Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Facebook
TwitterNon-traditional data signals from social media and employment platforms for MGTA stock analysis
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $1.27B in Market Capitalization this December of 2025, considering the latest stock price and the number of outstanding shares.Data for Dianthus Therapeutics | MGTA - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported 29.35M in Outstanding Shares in April of 2024. Data for Dianthus Therapeutics | MGTA - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported 53 in Employees for its fiscal year ending in December of 2023. Data for Dianthus Therapeutics | MGTA - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $577.44M in Assets for its fiscal quarter ending in September of 2025. Data for Dianthus Therapeutics | MGTA - Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $31K in Ordinary Share Capital for its fiscal quarter ending in December of 2024. Data for Dianthus Therapeutics | MGTA - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $413.82M in Current Assets for its fiscal quarter ending in September of 2025. Data for Dianthus Therapeutics | MGTA - Current Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $1.33M in Debt for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $0 in Loan Capital for its fiscal quarter ending in December of 2024. Data for Dianthus Therapeutics | MGTA - Loan Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $193K in Sales Revenues for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $546.45M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025. Data for Dianthus Therapeutics | MGTA - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $3.4M in Interest Income for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Interest Income including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $-0.88 in EPS Earnings Per Share for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - EPS Earnings Per Share including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $35.12M in Operating Expenses for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $-34.83M in EBITDA for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Ebitda including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $-31.63M in Net Income for its fiscal quarter ending in June of 2025. Data for Dianthus Therapeutics | MGTA - Net Income including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $6.7M in Trade Creditors for its fiscal quarter ending in September of 2025. Data for Dianthus Therapeutics | MGTA - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $23.86M in Current Liabilities for its fiscal quarter ending in September of 2025. Data for Dianthus Therapeutics | MGTA - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics reported $4.44M in Interest Expense on Debt for its fiscal quarter ending in September of 2024. Data for Dianthus Therapeutics | MGTA - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Dianthus Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.